Erasca Pill Shrinks Tumors in Early Cancer Trial
Early-stage results show ERAS-0015 reduced tumors in nearly half of patients with advanced pancreatic and lung cancers.
Updated on Nov. 22, 2026 in Cancer

Live Poll
Do you think new experimental cancer drugs will mostly help patients rather than harm them?
San Diego-based Erasca reported that its daily pill ERAS-0015 reduced tumors in nearly half of patients with advanced pancreatic and lung cancers in an early-stage clinical trial. The company said it will begin late-stage trials of ERAS-0015 and ERAS-4001 in 2027.
Why it matters
The results add to a growing field of drugs targeting mutant RAS proteins, which are involved in many pancreatic cancers. Early data remain limited to small patient groups, so the findings are preliminary and do not yet establish safety or effectiveness across broader populations.
The early trial reported a 44% substantial tumor-shrinkage rate among 25 pancreatic cancer patients on a 32 mg daily dose, and 69% positive results among patients with the two most common genetic variations of the disease. Its small sample sizes and the unexplained death of one patient on a 24 mg dose leave the drug's safety and true response rate unresolved.
The players
Erasca
Erasca is a San Diego-based drugmaker developing targeted therapies against mutant RAS proteins in cancer.
Dr. Jennifer Knox
Dr. Jennifer Knox is a physician who will supervise patients in the planned ERAS-0015 clinical trial in Canada.
The details
ERAS-0015 is a daily pill that blocks mutant RAS proteins that could allow cancer cells to multiply. Erasca also cited an earlier U.S.-led study published in The New England Journal of Medicine in May, which found that the experimental drug daraxonrasib doubled survival time in a clinical trial.
Timeline
May: The New England Journal of Medicine published the study showing daraxonrasib doubled survival time.
Friday, November 20, 2026: Erasca reported early ERAS-0015 trial results.
2027: Late-stage trials of ERAS-0015 and ERAS-4001 are scheduled to begin.
Health Landscape
ERAS-0015 extends the mutant-RAS approach that daraxonrasib pursued, which doubled survival time in a U.S.-led trial published in The New England Journal of Medicine in May. Erasca's pill is one of roughly 90 drugs in development targeting mutant RAS proteins, a field aimed at the 95% of pancreatic cancers that carry such mutations.
For patients with advanced pancreatic or lung cancer, the trial results suggest a potential future oral option, but the drug is not yet available outside clinical studies. Patients interested in participating should discuss eligibility and trial sites with their oncologists as later-stage trials open.
The takeaway
Early cancer drug results are promising but preliminary, and larger trials will determine whether tumor shrinkage translates into longer, better-quality lives for patients.
What happens next
Erasca plans to begin late-stage clinical trials of ERAS-0015 and ERAS-4001 in 2027.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by CTVNews.
Live Poll
Do you think new experimental cancer drugs will mostly help patients rather than harm them?






